|
Heart failure
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
No evidence was found to support an association between ACE genotype and HF.
|
14602526 |
2004 |
|
Heart failure
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Several polymorphisms that have supporting molecular and clinical data in the heart failure literature are reviewed, among them the beta1-adrenergic receptor variant Arg389Gly and the angiotensin converting enzyme gene insertion/deletion polymorphism.
|
20559955 |
2008 |
|
Heart failure
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Using the 2008-2012 IBM MarketScan Commercial database, we followed 26,439 individuals aged 18-64 years with newly diagnosed HF and calculated their adherence (using the proportion of days covered (PDC) algorithm) to the five guideline-recommended medication categories: angiotensin-converting enzyme inhibitors/angiotensin-receptor blockers; beta blockers; aldosterone receptor antagonists; hydralazine; and isosorbide dinitrate.
|
31545830 |
2019 |
|
Heart failure
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Angiotensin-converting enzyme inhibitor (ACEI) or angiotensin receptor blockers (ARB) were administered in 68.9% of HF discharged patients, beta-blockers in 84.8%, mineralocorticoid receptor antagonist (MRA) in 57.9%, diuretics in 85.9%, and digoxin in 23%.
|
28353316 |
2017 |
|
Heart failure
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
These findings suggest a potential pharmacogenetic interaction between the ACE D/I polymorphism and therapy with beta-blockers in the determination of heart failure survival.
|
11273991 |
2001 |
|
Heart failure
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Does angiotensin-converting enzyme polymorphism influence the clinical manifestation and progression of heart failure in patients with dilated cardiomyopathy?
|
10072245 |
1999 |
|
Heart failure
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
The male sibling developed heart failure and severe hypertension, and died at the age of 6 weeks despite of treatment with bisphosphonates, ACE inhibitors, and hydralazine.
|
15940697 |
2005 |
|
Heart failure
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
To assess the frequency of ACE gene polymorphisms in patients with ischemic HF in a Rio de Janeiro population, as well as its association with echocardiographic findings.
|
27812677 |
2016 |
|
Heart failure
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
The ACE genotype was determined in 171 patients selected with IDC in New York Heart Association functional class II to III heart failure and with a LV ejection fraction of < or = 40%.
|
10080429 |
1999 |
|
Heart failure
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Impact of angiotensin-converting enzyme gene polymorphism on neurohormonal responses to high- versus low-dose enalapril in advanced heart failure.
|
15523323 |
2004 |
|
Heart failure
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
To determine ACE polymorphism in patients with HF secondary to Chagas disease and patients with Chagas disease without systolic dysfunction, and to evaluate the relationship of the ACE polymorphism with different clinical variables.
|
28977050 |
2017 |
|
Heart failure
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
The risk of sudden death has changed over time among patients with symptomatic heart failure and reduced ejection fraction with the sequential introduction of medications including angiotensin-converting-enzyme inhibitors, angiotensin-receptor blockers, beta-blockers, and mineralocorticoid-receptor antagonists.
|
28679089 |
2017 |
|
Heart failure
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Angiotensin-converting enzyme gene DD polymorphism was associated with poorer survival and an increase in left ventricular mass in patients with idiopathic heart failure.
|
8752809 |
1996 |
|
Heart failure
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Preliminary studies suggest that the I/D polymorphism of the Angiotensin Converting Enzyme gene influence the development of left ventricular hypertrophy, a major determinant of heart failure.
|
10937920 |
1999 |
|
Heart failure
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Nonsteroidal anti-inflammatory drugs (NSAIDs) (OR: 6.839, 95 % CI = 4.392-10.648), angiotensin-converting enzyme inhibitors (ACEI) (OR: 7.846, 95 % CI = 5.161-11.928), angiotensin receptor blockers (ARB) (OR: 6.466, 95 % CI = 4.813-8.917), radiocontrast agents (OR: 8.850, 95 % CI = 5.857-13.372), hypertension (OR: 4.244, 95 % CI = 2.729-6.600), diabetes mellitus (OR: 2.303, 95 % CI = 1.411-3.761), heart failure (OR: 3.647, 95 % CI = 2.276-5.844) and presence of infection (OR: 3.149, 95 % CI = 1.696-5.845) were found as the risk factors for AKI-DO in elderly patients (p < 0.001 for all).
|
27704319 |
2017 |
|
Heart failure
|
0.600 |
GeneticVariation
|
disease |
LHGDN |
Effects of ACE gene insertion/deletion polymorphism on response to spironolactone in patients with chronic heart failure.
|
15121491 |
2004 |
|
Heart failure
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
We assessed the relation between the ACE I/D polymorphism and the risk of incident heart failure in normotensive and hypertensive subjects.
|
15571830 |
2004 |
|
Heart failure
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
The angiotensin-converting enzyme deletion allele (ACE D) decreases survival in patients with advanced heart failure.
|
15485441 |
2004 |
|
Heart failure
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
To assess the clinical effectiveness of beta-blocker therapy in individuals with heart failure (HF) and chronic lung disease and of angiotensin-converting enzyme inhibitors (ACE-Is) and angiotensin II receptor blockers (ARBs) in individuals with HF and chronic kidney disease.
|
28873219 |
2017 |
|
Heart failure
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
In men, the lowest hazards of death or hospitalisation for heart failure occurred at 100% of the recommended dose of ACE inhibitors or ARBs and β blockers, but women showed approximately 30% lower risk at only 50% of the recommended doses, with no further decrease in risk at higher dose levels.
|
31447116 |
2019 |
|
Heart failure
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
In HHF, the increase in the use of heart failure (HF) medications at hospital discharge was greater in non-COPD than in COPD for angiotensin-converting enzyme inhibitors (+13.7% vs. +7.2%), beta-blockers (+20.6% vs. +11.8%) and mineralocorticoid receptor antagonists (+20.9% vs. +17.3%), thus widening the gap in HF treatment already existing between the two groups at admission.
|
28949063 |
2018 |
|
Heart failure
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Determination of ACE genotype may help target therapy for patients with heart failure.
|
15542286 |
2004 |
|
Heart failure
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Common HF medications included beta-blockers (64%), angiotensin-converting enzyme inhibitors or angiotensin receptor blockers (62%), loop diuretics (46%), digoxin (11%), and aldosterone receptor antagonists (10%).
|
30299591 |
2019 |
|
Heart failure
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Reversal of remodelling can be achieved, and cardiac function improved in people with HF with reduced ejection fraction (HFrEF) by treatment with angiotensin-converting enzyme inhibitors and β-blockers.
|
30724013 |
2019 |
|
Heart failure
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
HF drug exposure-beta blockers (BB), angiotensin-converting enzyme inhibitors (ACEI), angiotensin receptor blockers (ARBs), aldosterone antagonists (AA), diuretics, digoxin, or ivabradine-was assessed quarterly using a Proportion of Days Covered ≥ 66% (≥ 60 days out of the 90 days of the quarter), by considering HF drugs individually or in combination.
|
31637454 |
2020 |